Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

— DERISC  

Official title:

An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02426541
• Other study ID #: D1690C00025
• Secondary ID: 2014-005377-36
• Status: Completed
• Phase: Phase 4
• First received: April 22, 2015
• Last updated: July 24, 2017
• Start date: March 23, 2015
• Est. completion date: April 28, 2016

Study information

• Verified date: July 2017
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: April 28, 2016
• Est. primary completion date: April 28, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 70 Years

Eligibility

Main Inclusion Criteria:

1. Provision of signed informed consent prior to any study specific procedures.

2. Female or male aged 35 to 70 years inclusive with suitable veins for cannulation or repeated venipuncture

3. Type 2 Diabetes mellitus defined as HbA1c of = 6.5% and = 10.5%.

4. Stable (= 3 months) T2D treatment with metformin and/or metformin+dipeptidyl peptidase-4 inhibitors (DPP-IV)

5. Body mass index (BMI) = 40 kg/m2.

6. Female subjects must be of non-childbearing potential, meeting at least one of the following criteria:

1. Hysterectomized females

2. Postmenopausal women, defined as women who have not had a menstrual period within 1 year

Main Exclusion Criteria:

1. Any condition that is contraindicated with MRI such as, but not limited to, having a pacemaker or claustrophobia.

2. Volume depleted patients. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.

3. Recent Cardiovascular Events in a patient:

• Acute Coronary Syndrome (ACS) within 2 months prior to enrolment

• Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment

• Acute Stroke or Transient Ischemic Attack (TIA) within two months prior to enrolment

• Less than two months post coronary artery revascularization

4. Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure.

5. Blood pressure at enrolment: Systolic BP =165 mm Hg and/or diastolic BP =100 mm Hg

6. Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of the first administration of the investigational product.

7. On insulin, GLP-1 or other oral antidiabetic drug treatment (metformin or both metformin and DPP-IV allowed) or using other medications known to affect glucose metabolism.

8. Any clinically significant abnormalities in physical examination, Electrocardiography (ECG) or clinical chemistry results as judged by the investigator. The following specific exclusion criteria apply to the selected Clinical Chemistry results:

1. Creatinine clearance <60mL/min (estimated with Cockroft-Gault formula).

2. Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN.

3. Total bilirubin (TB) >2.0 mg/dL (34.2 µmol/L).

9. Body weight loss greater than 5% within 3 months prior to Visit 1.

10. Previous PET scan

11. History of or presence of (as found at Visit 1) any clinically significant disease, disorder or condition which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Insulin Resistance
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Dapagliflozin
Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
• Placebo
Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

Locations

Country	Name	City	State
Finland	Research Site	Turku

Sponsors (5)

Lead Sponsor	Collaborator
AstraZeneca	43183 Mölndal, Antaros Medical AB, Bioventure Hub, Sweden

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake	Adjusted change from baseline in skeletal muscle insulin-stimulated gluocose uptake (umol/min/kg)	From baseline to Week 8
Secondary	Adjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake	Change in adipose tissue insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET	Baseline to Week 8
Secondary	Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8	Adjusted change in liver insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET	Baseline to Week 8